These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 24650691

  • 1. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva V, Deltenre P, Roudot-Thoraval F, Larrey D, Dhumeaux D, Mathurin P, Yazdanpanah Y.
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [Abstract] [Full Text] [Related]

  • 2. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
    Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A, WEF Study Group.
    J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
    Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.
    J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
    Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S.
    J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
    Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.
    J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.
    Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M.
    J Viral Hepat; 2015 Feb; 22(2):175-83. PubMed ID: 25040391
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
    Blázquez-Pérez A, San Miguel R, Mar J.
    Pharmacoeconomics; 2013 Oct; 31(10):919-31. PubMed ID: 24000086
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ, Khoo AL, Lin L, Teng M, Koh CJ, Lim SG, Lim BP, Dan YY.
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
    [Abstract] [Full Text] [Related]

  • 13. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
    Giménez-Manzorro Á, García-González X, Rodríguez-González CG, Ochoa-Palominos A, Sanjurjo-Sáez M, Clemente-Ricote G.
    Gastroenterol Hepatol; 2015 Dec; 38(10):575-82. PubMed ID: 26321320
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
    Deuffic-Burban S, Obach D, Canva V, Pol S, Roudot-Thoraval F, Dhumeaux D, Mathurin P, Yazdanpanah Y.
    J Viral Hepat; 2016 Oct; 23(10):767-79. PubMed ID: 27144512
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
    Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R, Gasbarrini A, Craxì A, Cammà C, WEF Study Group.
    Hepatology; 2014 May; 59(5):1692-705. PubMed ID: 24691835
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
    Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA.
    Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
    Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG.
    JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.